$ELOX News

Eloxx Pharmaceuticals Finalizes Design For Its EXPRESS Phase 2 Global Trial In Nonsense-Mutation Autosomal Dominant Polycystic Kidney Disease To Enrolol 60 Adults With Genetically Confirmed PKD1 Or PKD2 Nonsense Mutations

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

Cantor Fitzgerald Initiates Coverage On Eloxx Pharma with Overweight Rating

Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Guggenheim Reiterates Buy on Eloxx Pharma, Maintains $43 Price Target

LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

LifeSci Capital Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $40

Guggenheim Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $43

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals Reprices CEO Stock Options

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Eloxx Pharmaceuticals Reports Independent Confirmation Of Positive Biopsy Results In All Patients Treated With ELX-02 In Phase 2 Clinical Study For Alport Syndrome